The stock of Seres Therapeutics Inc (MCRB) has seen a -1.16% decrease in the past week, with a -35.91% drop in the past month, and a -23.33% decrease in the past quarter. The volatility ratio for the week is 8.78%, and the volatility levels for the past 30 days are at 10.54% for MCRB. The simple moving average for the last 20 days is -5.70% for MCRB stock, with a simple moving average of -17.82% for the last 200 days.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
The 36-month beta value for MCRB is at 2.02. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MCRB is 120.52M, and currently, shorts hold a 13.90% of that float. The average trading volume for MCRB on September 04, 2024 was 3.92M shares.
MCRB) stock’s latest price update
Seres Therapeutics Inc (NASDAQ: MCRB)’s stock price has increased by 4.74 compared to its previous closing price of 0.78. However, the company has seen a -1.16% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-09-04 that The heavy selling pressure might have exhausted for Seres Therapeutics (MCRB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Analysts’ Opinion of MCRB
Many brokerage firms have already submitted their reports for MCRB stocks, with Oppenheimer repeating the rating for MCRB by listing it as a “Outperform.” The predicted price for MCRB in the upcoming period, according to Oppenheimer is $12 based on the research report published on June 26, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $7. The rating they have provided for MCRB stocks is “Neutral” according to the report published on April 21st, 2023.
Goldman gave a rating of “Sell” to MCRB, setting the target price at $7 in the report published on July 23rd of the previous year.
MCRB Trading at -17.48% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.65% of loss for the given period.
Volatility was left at 10.54%, however, over the last 30 days, the volatility rate increased by 8.78%, as shares sank -18.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.10% upper at present.
During the last 5 trading sessions, MCRB fell by -1.16%, which changed the moving average for the period of 200-days by -31.63% in comparison to the 20-day moving average, which settled at $0.8605. In addition, Seres Therapeutics Inc saw -41.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from DesRosier Thomas, who sale 873 shares at the price of $0.84 back on Aug 16 ’24. After this action, DesRosier Thomas now owns 124,173 shares of Seres Therapeutics Inc, valued at $733 using the latest closing price.
von Moltke Lisa sale 973 shares at $0.84 during a trade that took place back on Aug 16 ’24, which means that von Moltke Lisa is holding 21,013 shares at $817 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -434.57 for the present operating margin
- -19.19 for the gross margin
The net margin for Seres Therapeutics Inc stands at -433.44. The total capital return value is set at -0.76. Equity return is now at value -538.57, with -44.53 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 4.54 points at debt to capital in total, while cash flow to debt ratio is standing at -1.63. The debt to equity ratio resting at -1.28. The interest coverage ratio of the stock is -10.06.
Currently, EBITDA for the company is -92.17 million with net debt to EBITDA at -0.93. When we switch over and look at the enterprise to sales, we see a ratio of 711.1. The receivables turnover for the company is 0.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.38.
Conclusion
In conclusion, Seres Therapeutics Inc (MCRB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
